Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 37

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Bronchiectasis

Recruiting

Study on Inhaled Colistimethate Sodium for Adults with Bronchiectasis and New Asymptomatic Pseudomonas Aeruginosa Infection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colistimethate Sodium
  • Sponsor:Philipps-Universitaet Marburg

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:ETOP IBCSG Partners Foundation

Glioma

Recruiting

Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University Of Cologne

Study on Tranexamic Acid to Prevent Surgery in Patients with Chronic Subdural Hematoma

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tranexamic Acid
  • Sponsor:Amsterdam UMC Stichting

Study of Metformin to Extend Pregnancy Duration in Women with Preterm Preeclampsia

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Metformin Hydrochloride
  • Sponsor:Amsterdam UMC Stichting

Study on the Effects of Ticagrelor and Acetylsalicylic Acid in Patients with Coronary Artery Disease Undergoing CABG Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Weill Medical College Of Cornell University

Study on the Effectiveness of INCB000928 for Patients with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:INCB000928
  • Sponsor:Incyte Corp.

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:University Medical Center Hamburg-Eppendorf

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.